Claims for Patent: 4,439,521

Summary for Patent: 4,439,521

Title:	Method for producing self-reproducing mammalian pancreatic islet-like structures
Abstract:	Method for producing pancreatic islet-like structures (ILS\'s) having histology and insulin-producing properties corresponding to those of fetal pancreatic islets and islets from adult animals maintained in culture. The ILS\'s are produced by culturing isolated natural pancreatic islets, pancreatic duct pieces, cell clusters consisting of mildly digested pieces of pancreas, cell tissues obtained as by-products of the culturing methods, or previously-produced ILS\'s, in attachment to a substrate.
Inventor(s):	Archer; Michael C. (Mississauga, CA), Jain; Kanti (Toronto, CA)
Assignee:	Ontario Cancer Institute (Toronto, CA)
Application Number:	06/313,494
Patent Claims:	1. A method for producing mammalian pancreatic islet-like structures hereinafter called ILS's, having histological characteristics and insulin-producing properties corresponding to those of natural isolated fetal pancreatic islets and islets obtained from adult animals maintained in culture, comprising establishing under conditions promoting the growth of mammalian cells, a culture comprising at least one pancreatic tissue-derived body attached to a substrate compatible with mammalian cells and capable of accepting the attachment of mammalian pancreatic islet tissue thereto, and immersed in a liquid tissue culture medium capable of sustaining mammalian cell growth, said body being selected from the group consisting of: (a) intact mammalian pancreatic islets isolated directly from postpartal pancreatic tissue and present in the culture at an islet population density of less than about 10 islets per ml of the liquid culture medium; (b) pieces of mammalian postpartal pancreatic duct; (c) clusters of coherent pancreatic cells obtained by mild digestion of pieces of whole mammalian postpartal pancreas with a solution of a connective tissue-lysing enzyme, said clusters being substantially free of pancreatic exocrine tissue; (d) cells characterized by having an oblong flat configuration with highly serrated ends and tenacious attachment to the substrate and obtained by culturing a body selected from the group consisting of said bodies (a), (b), and (c) above and (e) below for prolonged periods in said culture under said mammalian cell-growth promoting conditions; (e) ILS's obtained by culturing a body selected from the group consisting of said bodies (a), (b), (c), and (d) for prolonged periods under said mammalian cell-growth promoting conditions; and maintaining said culture for a period sufficient to permit neogenesis of discrete ILS's connected to cell tissue outgrowing from the body and attached to the substrate; detaching said ILS's from the said outgrowing tissue; and recovering said detached ILS's from the culture. 2. Method as claimed in claim 1 wherein said at least one body comprises a piece of mammalian pancreatic duct. 3. A method as claimed in claim 2 wherein said duct piece has a maximum dimension of from about 0.5 to about 5 mm. 4. Method as claimed in claim 3 wherein said maximum dimension is about 0.5 mm to about 2 mm. 5. Method as claimed in claim 1 wherein said at least one body comprises a plurality of mammalian pancreatic duct pieces. 6. A method as claimed in claim 5 wherein said pieces are maintained on the substrate at a spacing sufficient to avoid overlapping of tissues outgrowing from adjacent pieces. 7. Method as claimed in claim 5 wherein said pieces are maintained on the substrate at a spacing of at least about 5 mm. 8. Method as claimed in claim 7 wherein said spacing is at least about 10 mm. 9. Method as claimed in claim 5 comprising initially seeding a plurality of said duct pieces into a culture vessel providing said substrate and containing said culture medium, and removing from the culture vessel any duct pieces that remain unattached to the substrate after culturing for a period of about 2 weeks. 10. Method as claimed in claim 9 including the step of removing from the culture vessel any detached duct pieces that float in the medium after a period of about 4 weeks from the data of initial seeding. 11. Method as claimed in claim 2 comprising maintaining the culture for a period of at least about 2 weeks. 12. Method as claimed in claim 11 wherein the liquid culture medium is changed at intervals of about 1 to 7 days throughout the period of culturing. 13. Method as claimed in claim 1 wherein said at least one body comprises an isolated intact mammalian pancreatic islet. 14. Method as claimed in claim 1 wherein said at least one body comprises a plurality of isolated intact mammalian pancreatic islets. 15. Method as claimed in claim 14 wherein said islets are maintained on the substrate at a density of less than about 5 islets per ml of culture medium. 16. Method as claimed in claim 15 wherein said density is about 1 to 3 islets per ml of culture medium. 17. Method as claimed in claim 14 comprising intitially seeding said islets in a culture vessel, providing said substrate, and containing said culture medium, at a density in excess of 10 inlets per ml of culture medium, and removing any detached islets from the culture vessel at intervals during the first 10 weeks of culturing. 18. Method as claimed in claim 13 comprising maintaining the culture for a period of at least about 8 weeks. 19. Method as claimed in claim 18 including changing the liquid culture medium initially at intervals of about 12 to 24 hours for a period of about 3 to 4 days from the data of seeding and subsequently at intervals of about 5 to 10 days. 20. Method as claimed in claim 14 wherein said islets are obtained by digestion of pieces of whole pancreatic tissue under mild digestion conditions with a solution of a connective tissue-lysing enzyme for a period sufficient to liberate the islets from the tissue. 21. Method as clamied in claim 20 wherein said pieces are contacted with said enzyme solution for the minimum period of time required to liberate the islets. 22. Method as claimed in claim 20 wherein digestion is conducted under such mild conditions that the liberated islets have vestiges of pancreatic ductules discernible at their peripheries. 23. Method as claimed in claim 1 wherein said at least one body comprises a culster of pancreatic cells obtained by mild digestion of pieces of whole mammalian pancreas with a solution of connective tissue-lysing enzyme. 24. Method as claimed in claim 23 wherein said pieces have a maximum dimension of about 0.5 to about 5 mm. 25. Method as claimed in claim 24 wherein said maximum dimension is about 0.5 to about 2 mm. 26. Method is claimed in claim 20 or 23 wherein said enzyme solution has a tissue-lysing potency no greater than that of a reference solution containing about 1,500 Units of collagenase per ml. 27. Method as claimed in claim 20 or 23 wherein said enzyme solution has a tissue-lysing potency no greater than that of a reference solution containing about 1,000 Units of collagenase per ml. 28. Method as claimed in claim 20 or 23 wherein said enzyme solution has a tissue lysing potency no greater than that of a reference solution containing about 750 Units of collagenase per ml. 29. Method as claimed in claim 20 or 23 wherein said mild digestion is such that the degree of tissue lysis corresponds approximately to that obtained from digestion with a collagenase solution containing about 750 collagenase Units per ml for about 12 to 15 minutes at about 37.degree. C. 30. Method as claimed in claim 20 or 23 wherein said enzyme solution contains a mixture of collagenase and hyaluronidase. 31. Method as claimed in claim 1 wherein said at least one body comprises a plurality of said clusters as defined in paragraph (c) thereof. 32. Method as claimed in claim 31 wherein said clusters are seeded in a culture vessel providing said substrate and containing said culture medium at a spacing that avoids overlapping on the substrate of epitheloid monolayers that form from the clusters. 33. Method as claimed in claim 23 wherein said culture is maintained for a period of at least about 25 days. 34. Method as claimed in claim 33 including changing the liquid culture medium initially at intervals of about 12 to 24 hours for the first 3 to 4 days from the data of seeding and subsequently at intervals of about 5 to 10 days. 35. Method as claimed in claim 1 wherein said liquid culture medium contains glucose at a molar concentration of about 5 to 20 mM. 36. Method as claimed in claim 32 wherein said glucose concentration is about 10 mM. 37. Method as claimed in claim 1 wherein said medium is maintained equilibrated with a 5% CO.sub.2 /air mixture. 38. Method as claimed in claim 1 wherein said medium is maintained under a water-saturated atmosphere. 39. Method as claimed in claim 1 wherein said culture medium contains mammalian serum. 40. Method as claimed in claim 39 wherein the content of mammalian serum is about 5 to 20% by volume based on the volume of the mixture. 41. Method as claimed in claim 39 wherein the serum is heterologous with respect to said body. 42. Method as claimed in claim 39 or 40 wherein said serum is fetal calf serum. 43. Method as claimed in claim 39 wherein the medium contains in admixture about 15% by volume fetal calf serum based on the volume of the mixture. 44. Method as claimed in claim 1 wherein the culture medium is maintained at a temperature of 35.degree. to 40.degree. C. 45. Method as claimed in claim 44 wherein said temperature is about 37.degree. C. 46. Method as claimed in claim 1 wherein the culture medium contains at least one antibiotic present in an effective microorganism growth-inhibitive concentration. 47. Method as claimed in claim 46 wherein the medium contains about 50 to about 200 .mu.U/ml penicillin and about 50 to about 100 .mu.g/ml streptomycin. 48. Method as claimed in 47 wherein the medium contains about 100 .mu.U/ml penicillin and about 100 .mu.g/ml streptomycin. 49. A method for producing mammalian pancreatic islet-like structures hereinafter called ILS's, having histological characteristics and insulin-producing properties similar to those of natural isolated fetal pancreatic islets and islets obtained from adult animals maintained in culture, comprising sub-culturing neogenetic ILS's harvested from a culture of pancreatic tissue-derived bodies, and harvesting neogenetic ILS's from the sub-culture. 50. A method as claimed in claim 49 wherein the sub-culturing comprises establishing under conditions promoting the growth of mammalian cells, a culture comprising the first-mentioned neogenetic ILS's attached to a substrate compatible with mammalian cells and capable of accepting the attachment of pancreatic islet tissue thereto, and immersed in a liquid tissue culture medium capable of sustaining mammalian cell growth, and maintaining the culture for a period sufficient to permit neogenesis of discrete ILS's connected to cell tissue outgrowing from said first-mentioned neogenetic ILS's.

Details for Patent 4,439,521

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640	05/05/2004		2039-03-29
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640	12/02/2004		2039-03-29
Amphastar Pharmaceuticals, Inc.	AMPHADASE	hyaluronidase	Injection	021665	10/26/2004		2039-03-29
Akorn, Inc.	HYDASE	hyaluronidase	Injection	021716	10/25/2005		2039-03-29